07:49 AM EDT, 08/13/2024 (MT Newswires) -- Centessa Pharmaceuticals ( CNTA ) reported a Q2 net loss Tuesday of $0.40 per diluted share, widening from a loss of $0.26 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.38.

The company did not report revenue for the quarter ended June 30.

Centessa said it ended Q2 with $294.8 million in cash, cash equivalents and short-term investments, which is enough to fund operations until mid-2026 "without drawing on the remaining available tranches under the Oberland credit facility."